Management of Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Management of Radioactive Iodine-Refractory Differentiated Thyroid Cancer
7:00 – 9:30 pm
Hyatt Regency Orlando- Regency Ballroom S
CLICK "BEGIN" TO EVALUATE SESSIONS, CLAIM CME, AND PRINT A CERTIFICATE OF ATTENDANCE OR CERTIFICATE OF PARTICIPATION.
Target Audience
This continuing medical education activity should be of substantial interest to the community of clinical endocrinologists, internists, primary care physicians, endocrine nurses, and other healthcare providers involved in the care of patients with thyroid cancer.
Learning Objectives
Upon completion of this educational activity, learners will be better able to:
- Personalize treatment selection for patients with RAI-refractory DTC based on available data and approved agents
- Mitigate and manage adverse events to preserve patient function and improve outcomes
- Review late-stage clinical trials of emerging agents for which patients with RAI-refractory DTC may be eligible
Additional Information
Associate Vice Provost, Clinical Research
Naguib Samaan Distinguished Professor in Endocrinology
Chair, Department of Endocrine Neoplasia and Hormonal Disorders
The University of Texas MD Anderson Cancer Center
Associate Professor and Faculty Director of Clinical Research,
Dept. of Endocrine Neoplasia & Hormonal Disorders
University of Texas M.D. Anderson Cancer Center
DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Steven I. Sherman, MD: Consultant, Eisai, Sanofi, Veracyte, Inc., LOXO, Bristol-Myers Squibb,
Scientific Board Member: Novo Nordisk
Maria E. Cabanillas, MD: Advisory Group Member, LOXO, Blueprint; Principal Investigator, Eisai, Genentech, Inc., Kura, Exelixis
Lori J. Wirth, MD: Advisory Group Member, Amgen, Eisai, Merck & Co., Blueprint Medicines, Loxo
The following SPC member who reviewed content for this activity reported the following financial relationships:
Giuseppe Barbesino, MD: Spouse, employee of Genzyme
The following SPC Committee members reported financial relationships:
Zahid Ahmad, MD: Research Support, Regeneron, FH Foundation; Consultant, Regeneron; Speaker, Amgen, Genzyme, Sanofi
Andrew Ahmann, MD: Research Support, DexCom, Lexicon, Medtronic, Novo Nordisk; Consultant, Dexco, Novo Nordisk, Trividia Health
John Carmichael, MD: Research Support, Novo Nordisk, Chiasma, Novartis, Pfizer, Strongbridge Biopharma; Speaker, Novartis; Advisory Board, Pfizer, Chiasma, Ionis Pharmaceuticals
Natalie Cusano, MD: Research Support, Shire; Speaker, Shire
Joan Han, MD: Research Support, Rhythm Pharmaceutical
Alan Kelly, MD: Speaker, Eli Lilly
E Michael Lewiecki, MD: Consultant, Amgen, Merck, Eli Lilly, Radius Health, Shire, Abbvie and Alexion; Speaker, Alexion, Shire; Research Grant Support, Amgen, Eli Lilly, Merck
Lisa Nachtigall, MD: Consultant, Ipsen, Novartis, Corcept; Grant Support/Investigator, Chiasma
Neda Rasouli, MD: Research Support, Novo Nordisk, Calibra, INTARCIA Therapeutics, GlaxoSmithKline, Bristol Meyer Squibb, AstraZeneca /Amylin, Ionis Pharmaceuticals, Boehringer Ingelheim
The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.
The following SPC members reported no relevant financial relationships: Connie Newman, MD, Amy Rothberg, MD
Available Credit
- 2.50 AMA PRA Category 1 Credits™
- 2.50 CME Certificate of Participation